Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Liabilities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Total Liabilities for 16 consecutive years, with $22.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 17.92% to $22.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.0 million, a 17.92% decrease, with the full-year FY2024 number at $27.0 million, down 29.06% from a year prior.
  • Total Liabilities was $22.0 million for Q3 2025 at Gyre Therapeutics, down from $23.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $38.1 million in Q4 2023 to a low of $1.6 million in Q3 2022.
  • A 5-year average of $18.1 million and a median of $16.6 million in 2021 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 90.76% in 2022, then skyrocketed 315.17% in 2024.
  • Gyre Therapeutics' Total Liabilities stood at $14.6 million in 2021, then fell by 13.98% to $12.5 million in 2022, then soared by 203.65% to $38.1 million in 2023, then dropped by 29.06% to $27.0 million in 2024, then decreased by 18.65% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Total Liabilities are $22.0 million (Q3 2025), $23.2 million (Q2 2025), and $25.5 million (Q1 2025).